Industry Sees Much To Improve In Germany's New High-Risk Medtech Assessment Scheme
Executive Summary
Only two of eight treatments passed muster under Germany's new NUBs scheme for assessing the benefit of high-risk products for inpatient use. As with the country's outpatient assessment counterpart, industry is pushing for changes.
You may also be interested in...
Germany Votes: But What Will Change For Health Care, Medtech Post-Election?
The German Bundestagswahl – the 2017 general election – looks likely to deliver a fourth straight victory for CDU chief Angela Merkel, Europe's most powerful politician and arguably the world's most powerful national female leader. But she will have to invite coalition partners, as in her previous three regimes, which could spell changes for health and the other ministerial portfolios that touch on medtech.
German Medtechs Aim To Score Useful Points In 2017 Election Year
The 2017 German national election, set for September 24, is not only a chance for Angela Merkel to secure a fourth term in office as Chancellor, but also an opportunity for the medtech industry to tell lawmakers how they can make the health-care system better. The medtech industry has made ten demands of the new government, with recent opinion polls favoring the status quo.
Germany – Still Europe's Stand-Out Medtech Innovation Market
Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.